Inizio contenuto principale del sito

Aimo, A.; Pateras, K.; Stamatelopoulos, K.; Bayes-Genis, A.; Lombardi, C. M.; Passino, C.; Emdin, M.; Georgiopoulos, G.

Relative Efficacy of Sacubitril-Valsartan, Vericiguat, and SGLT2 Inhibitors in Heart Failure with Reduced Ejection Fraction: a Systematic Review and Network Meta-Analysis Open new browser tab

(2020)

Aimo, A.; Emdin, M.; Passino, C.

Intracoronary Delivery of Mitochondria to Prevent Ischemia–Reperfusion Injury: Challenging Pathway From Bench to Bedside Open new browser tab

(2020)

Aimo, A.; Emdin, M.; Barison, A.

Magnetic Resonance to Diagnose Cardiac Amyloidosis: Is it Already Time to Discard Contrast Agents? Open new browser tab

(2020)

Aimo, A.; Vergaro, G.; Castiglione, V.; Rapezzi, C.; Emdin, M.

Safety and Tolerability of Neurohormonal Antagonism in Cardiac Amyloidosis Open new browser tab

(2020)

Grigoratos, C.; Aimo, A.; Rapezzi, C.; Genovesi, D.; Barison, A.; Aquaro, G. D.; Vergaro, G.; Pucci, A.; Passino, C.; Marzullo, P.; Gimelli, A.; Emdin, M.

Diphosphonate single-photon emission computed tomography in cardiac transthyretin amyloidosis Open new browser tab

(2020)

Aimo, A.; Rapezzi, C.; Arzilli, C.; Vergaro, G.; Emdin, M.

Safety and efficacy of levosimendan in patients with cardiac amyloidosis Open new browser tab

(2020)

Figliozzi, S.; Masci, P. G.; Ahmadi, N.; Tondi, L.; Koutli, E.; Aimo, A.; Stamatelopoulos, K.; Dimopoulos, M. -A.; Caforio, A. L. P.; Georgiopoulos, G.

Predictors of adverse prognosis in COVID-19: A systematic review and meta-analysis Open new browser tab

(2020)

Aimo, Alberto; Bianchi, Giacomo; Vergaro, Giuseppe

Integrated Imaging to Investigate Low-Flow Alarms of Left Ventricular Assist Devices Open new browser tab

(2020)

Aimo, Alberto; Emdin, Michele; Musetti, Veronica; Pucci, Angela; Vergaro, Giuseppe

Abdominal Fat Biopsy for the Diagnosis of Cardiac Amyloidosis Open new browser tab

(2020)

Aimo, A.; Egea, O. I.; Emdin, M.; Bayes-Genis, A.

Overlapping Effects of miR-21 Inhibition and Drugs for Idiopathic Pulmonary Fibrosis: Rationale for Repurposing Nintedanib as a Novel Treatment for Ischemia/Reperfusion Injury Open new browser tab

(2021)

Subscribe to